CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injury

Cell Death Dis. 2013 Jun 20;4(6):e679. doi: 10.1038/cddis.2013.198.

Abstract

Cytokines such as interleukins are known to be involved in the development of neuropathic pain through activation of neuroglia. However, the role of chemokine (C-C motif) ligand 1 (CCL-1), a well-characterized chemokine secreted by activated T cells, in the nociceptive transmission remains unclear. We found that CCL-1 was upregulated in the spinal dorsal horn after partial sciatic nerve ligation. Therefore, we examined actions of recombinant CCL-1 on behavioural pain score, synaptic transmission, glial cell function and cytokine production in the spinal dorsal horn. Here we show that CCL-1 is one of the key mediators involved in the development of neuropathic pain. Expression of CCL-1 mRNA was mainly detected in the ipsilateral dorsal root ganglion, and the expression of specific CCL-1 receptor CCR-8 was upregulated in the superficial dorsal horn. Increased expression of CCR-8 was observed not only in neurons but also in microglia and astrocytes in the ipsilateral side. Recombinant CCL-1 injected intrathecally (i.t.) to naive mice induced allodynia, which was prevented by the supplemental addition of N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801. Patch-clamp recordings from spinal cord slices revealed that application of CCL-1 transiently enhanced excitatory synaptic transmission in the substantia gelatinosa (lamina II). In the long term, i.t. injection of CCL-1 induced phosphorylation of NMDA receptor subunit, NR1 and NR2B, in the spinal cord. Injection of CCL-1 also upregulated mRNA level of glial cell markers and proinflammatory cytokines (IL-1β, TNF-α and IL-6). The tactile allodynia induced by nerve ligation was attenuated by prophylactic and chronic administration of neutralizing antibody against CCL-1 and by knocking down of CCR-8. Our results indicate that CCL-1 is one of the key molecules in pathogenesis, and CCL-1/CCR-8 signaling system can be a potential target for drug development in the treatment for neuropathic pain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / administration & dosage
  • Animals
  • Cells, Cultured
  • Chemokine CCL1 / antagonists & inhibitors
  • Chemokine CCL1 / physiology*
  • Dizocilpine Maleate / administration & dosage
  • Ganglia, Spinal / metabolism
  • Gene Expression
  • Gene Knockdown Techniques
  • Glutamic Acid
  • Hyperalgesia / drug therapy
  • Injections, Spinal
  • Male
  • Mice
  • Mice, Transgenic
  • Neuralgia / drug therapy
  • Neuralgia / metabolism*
  • Neuroglia / metabolism
  • Nociception
  • Peripheral Nerve Injuries / drug therapy
  • Peripheral Nerve Injuries / metabolism
  • Phosphorylation
  • Protein Processing, Post-Translational
  • RNA, Small Interfering / genetics
  • Receptors, CCR8 / genetics
  • Receptors, CCR8 / metabolism
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Spinal Cord / metabolism
  • Spinal Cord / physiopathology*

Substances

  • Analgesics
  • Ccl1 protein, mouse
  • Ccr8 protein, mouse
  • Chemokine CCL1
  • RNA, Small Interfering
  • Receptors, CCR8
  • Receptors, N-Methyl-D-Aspartate
  • Glutamic Acid
  • Dizocilpine Maleate